Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up – Should You Buy?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $36.16, but opened at $37.28. Supernus Pharmaceuticals shares last traded at $37.09, with a volume of 42,602 shares changing hands.

Analysts Set New Price Targets

SUPN has been the topic of several research analyst reports. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 0.0 %

The business has a fifty day moving average price of $35.30 and a 200-day moving average price of $31.94. The company has a market cap of $2.00 billion, a P/E ratio of 33.80 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.29) earnings per share. As a group, research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the transaction, the director now owns 13,315 shares in the company, valued at $487,595.30. The trade was a 51.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jack A. Khattar sold 125,000 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock valued at $5,660,180 over the last quarter. 9.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SUPN. Franklin Resources Inc. grew its position in Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after acquiring an additional 2,121 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Barclays PLC boosted its stake in shares of Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of Supernus Pharmaceuticals by 1.6% during the third quarter. Stifel Financial Corp now owns 69,134 shares of the specialty pharmaceutical company’s stock worth $2,156,000 after purchasing an additional 1,093 shares during the last quarter. Finally, Systematic Financial Management LP acquired a new position in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $879,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.